First-in-human assessment of a new device shows improved outcomes in men with stress urinary incontinence, suggesting effective treatment.
In men with SUI, the UroActive® device demonstrates promising feasibility, safety, and functional outcomes during the 365 days post-activation. Patients experienced substantial symptom improvement and high satisfaction, with no surgical revisions. Larger studies with extended follow-up are needed to confirm these findings and assess long-term device performance.
No takes yet. Share an insight, caveat, or question.
Mozer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: